BLMS: AI 评分 49/100 — AI 分析 (4月 2026)

Bloomios, Inc. manufactures and distributes cannabidiol (CBD) products, including edibles, tinctures, and topicals, through wholesale and retail channels. The company operates in the competitive and evolving market for hemp-derived supplements and cosmetic products.

Key Facts: AI Score: 49/100 Sector: Healthcare

公司概况

概要：

Bloomios, Inc. focuses on manufacturing and distributing a range of cannabidiol (CBD) products, including edibles, tinctures, and topicals. Operating within the specialty and generic drug manufacturing sector, the company targets both wholesale and retail distribution channels for its hemp-derived supplements and cosmetic products.

BLMS是做什么的？

Bloomios, Inc., formerly known as XLR Medical Corp., rebranded in April 2021 to concentrate on the cannabidiol (CBD) market. Incorporated in 2001 and headquartered in Santa Barbara, California, the company manufactures, markets, and distributes a diverse portfolio of CBD products. These include edibles, tinctures, oils, salves, capsules, balms, lotions, creams, beverages, and pet treats. Bloomios distributes its hemp-derived supplements and cosmetic products through both wholesale partnerships and direct retail channels, aiming to capitalize on the growing consumer interest in CBD-based health and wellness solutions. The company's strategy involves expanding its product line and distribution network to reach a broader customer base in the competitive CBD market. Bloomios faces the challenges of navigating regulatory complexities and differentiating itself in a crowded field of CBD product manufacturers and distributors. The company's success depends on effective marketing, product innovation, and adherence to quality standards to build consumer trust and brand loyalty.

BLMS的投资论点是什么？

Bloomios, Inc. operates in the high-growth CBD market, but its financial performance and OTC listing present significant risks. With a negative profit margin of -226.7% and a market capitalization of $0.00B as of March 2026, the company's financial stability is uncertain. The company's gross margin stands at 36.7%. Key growth catalysts include expanding distribution channels and introducing new product lines. However, investors should be aware of the risks associated with OTC-listed companies, including limited liquidity and regulatory uncertainty. The company's ability to achieve profitability and navigate the competitive landscape will be critical to its long-term success.

BLMS在哪个行业运营？

Bloomios, Inc. operates within the rapidly expanding CBD market, which has seen significant growth due to increasing consumer acceptance of CBD products for various health and wellness applications. The market is characterized by intense competition, with numerous companies offering similar products. Key trends include the development of innovative CBD formulations, the expansion of distribution channels, and increasing regulatory scrutiny. Bloomios competes with other CBD manufacturers and distributors, including AIDA, ASFX, CENBF, MJNE, and SAGD, all of which are navigating the evolving regulatory landscape and striving to establish brand recognition.

Drug Manufacturers - Specialty & Generic

Healthcare

BLMS有哪些增长机遇？

Expansion of Product Line: Bloomios can drive growth by introducing new and innovative CBD products, such as specialized formulations targeting specific health conditions or novel delivery methods. The market for CBD-infused beverages and edibles is projected to reach $2.8 billion by 2028, presenting a significant opportunity for Bloomios to capture market share through product innovation and effective marketing.
Strategic Partnerships: Forming strategic partnerships with established retailers and distributors can significantly expand Bloomios' market reach and brand visibility. Collaborating with national pharmacy chains or health food stores could provide access to a broader customer base and enhance the company's credibility. The timeline for establishing such partnerships is estimated at 12-18 months, with potential revenue impact within the following year.
E-commerce Expansion: Investing in a robust e-commerce platform and digital marketing strategies can enable Bloomios to reach a global audience and drive online sales. The online CBD market is experiencing rapid growth, with projections estimating a market size of $16 billion by 2027. By optimizing its online presence and offering a seamless customer experience, Bloomios can capitalize on this trend and increase its direct-to-consumer sales.
White Label and Private Label Opportunities: Bloomios can leverage its manufacturing capabilities to offer white label and private label CBD products to other companies. This can provide a stable revenue stream and diversify the company's customer base. The market for white label CBD products is growing as more businesses seek to enter the CBD market without investing in their own manufacturing infrastructure. Bloomios can target small to medium-sized businesses in the health and wellness sector.
International Expansion: Exploring international markets, particularly in Europe and Asia, can unlock significant growth opportunities for Bloomios. The European CBD market is projected to reach $1.5 billion by 2025, while the Asian market is also showing increasing interest in CBD products. However, international expansion requires careful consideration of regulatory requirements and cultural differences. Bloomios can start by targeting countries with more favorable CBD regulations and establishing partnerships with local distributors.

Market Cap of $0.00B indicates a micro-cap company with high growth potential but also significant risk.
Negative P/E ratio of -0.00 reflects the company's current lack of profitability.
Profit Margin of -226.7% highlights significant operational challenges and the need for improved cost management.
Gross Margin of 36.7% suggests potential for profitability if operating expenses are better controlled.
Beta of -0.53 indicates the stock is less volatile than the market, but this may also reflect limited trading activity.

BLMS提供哪些产品和服务？

Manufactures cannabidiol (CBD) products.
Markets CBD products through various channels.
Distributes CBD products to wholesale and retail customers.
Offers edibles, tinctures, oils, salves, capsules, balms, lotions, creams, and beverages.
Provides CBD products for both human and pet consumption.
Sells hemp-derived supplements and cosmetic products.

BLMS如何赚钱？

Manufacturing and selling CBD products.
Generating revenue through wholesale distribution to retailers.
Generating revenue through direct-to-consumer retail sales.
Offering a diverse range of CBD product categories to cater to different consumer preferences.

Retail consumers seeking CBD products for health and wellness.
Wholesale distributors and retailers selling CBD products.
Pet owners seeking CBD products for their pets.
Customers interested in various forms of CBD consumption (e.g., edibles, topicals, tinctures).

Product diversification across multiple CBD product categories.
Established wholesale and retail distribution channels.
Proprietary formulations and manufacturing processes.
Brand recognition and customer loyalty in the CBD market.

什么因素可能推动BLMS股价上涨？

Upcoming: Potential regulatory changes in the CBD market could create new opportunities or challenges for Bloomios.
Ongoing: Expansion of distribution channels through strategic partnerships with retailers.
Ongoing: Introduction of new and innovative CBD products to meet evolving consumer demand.
Ongoing: Increased consumer awareness and acceptance of CBD products.
Ongoing: Development of white label and private label opportunities to diversify revenue streams.

BLMS的主要风险是什么？

Potential: Increased competition from larger companies entering the CBD market.
Potential: Negative publicity or health concerns related to CBD products.
Potential: Fluctuations in the price of hemp and other raw materials.
Ongoing: Regulatory uncertainty and potential restrictions on CBD products.
Ongoing: Limited financial resources and negative profit margin.

BLMS的核心优势是什么？

Diverse product range across multiple CBD categories.
Established wholesale and retail distribution channels.
Focus on hemp-derived supplements and cosmetic products.
Experienced management team in the CBD industry.

BLMS的劣势是什么？

Negative profit margin and limited financial resources.
Small market capitalization and OTC listing.
Limited brand recognition compared to larger competitors.
Dependence on the evolving regulatory landscape for CBD products.

BLMS有哪些机遇？

Expansion into new geographic markets.
Development of innovative CBD formulations and delivery methods.
Strategic partnerships with established retailers and distributors.
Increased consumer awareness and acceptance of CBD products.

BLMS面临哪些威胁？

Intense competition from other CBD manufacturers and distributors.
Changing regulatory requirements and potential restrictions on CBD products.
Fluctuations in the price of hemp and other raw materials.
Negative publicity or health concerns related to CBD products.

BLMS的竞争对手是谁？

AIDA Diagnostics GmbH — Focuses on diagnostic solutions, differing from Bloomios' CBD product focus. — (AIDA)
Asante Financial Services Group — Provides financial services, unlike Bloomios' CBD manufacturing and distribution. — (ASFX)
Cen Biotech Inc — Engaged in cannabis cultivation and processing, a broader scope than Bloomios' CBD product focus. — (CENBF)
MJ Newswire Inc — A media and news distribution company in the cannabis sector, not a direct product competitor. — (MJNE)
Sage Diagnostics Inc — Focuses on diagnostic testing, differing from Bloomios' CBD product manufacturing. — (SAGD)

Key Metrics

MoonshotScore: 49/100

Company Profile

CEO: Michael Hill
Headquarters: Santa Barbara, US
Employees: 3
Founded: 2003

AI Insight

AI analysis pending for BLMS

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Bloomios, Inc. do?

Bloomios, Inc. is a manufacturer and distributor of cannabidiol (CBD) products, catering to both human and pet consumption. The company offers a diverse range of CBD products, including edibles, tinctures, oils, salves, capsules, balms, lotions, creams, beverages, and pet treats. Bloomios distributes these hemp-derived supplements and cosmetic products through wholesale and retail channels, aiming to capitalize on the growing demand for CBD-based health and wellness solutions. The company's business model focuses on product innovation, effective marketing, and strategic distribution partnerships to reach a broad customer base.

What do analysts say about BLMS stock?

As of March 2026, there is no readily available analyst coverage for Bloomios, Inc. (BLMS) due to its OTC listing and small market capitalization. Key valuation metrics, such as P/E ratio and profit margin, indicate financial challenges. Potential investors should conduct thorough due diligence and consider the risks associated with OTC-listed companies before making any investment decisions. The company's growth prospects depend on its ability to improve profitability, expand its market share, and navigate the evolving regulatory landscape for CBD products.

What are the main risks for BLMS?

Bloomios, Inc. faces several key risks, including intense competition in the CBD market, regulatory uncertainty surrounding CBD products, and fluctuations in the price of hemp and other raw materials. The company's negative profit margin and limited financial resources also pose significant challenges. As an OTC-listed company, Bloomios is subject to limited liquidity and higher price volatility. Investors should carefully consider these risks before investing in BLMS.

What revenue streams does Bloomios, Inc. have in healthcare?

Bloomios, Inc. generates revenue primarily through the sale of its cannabidiol (CBD) products. These revenue streams are derived from both wholesale and retail distribution channels. The company's product line includes edibles, tinctures, oils, salves, capsules, balms, lotions, creams, beverages, and pet treats, all of which contribute to the overall revenue. Bloomios focuses on marketing these products as hemp-derived supplements and cosmetic products to appeal to health-conscious consumers. The company's success depends on its ability to effectively market and distribute these products while navigating the evolving regulatory landscape for CBD in the healthcare sector.

How does Bloomios, Inc. navigate regulatory approval processes?

As a manufacturer and distributor of cannabidiol (CBD) products, Bloomios, Inc. operates in a complex and evolving regulatory environment. The company must comply with various federal, state, and local regulations governing the production, labeling, and sale of CBD products. While CBD products derived from hemp are generally legal under federal law, specific regulations vary by state. Bloomios must stay informed about these changing regulations and ensure its products meet all applicable requirements. The company's strategy involves working closely with legal counsel and industry experts to navigate the regulatory landscape and maintain compliance. Bloomios also monitors pending legislation and advocates for reasonable regulations that support the growth of the CBD industry.